AMENDMENTS TO THE CLAIMS

Please amend the claims as follows. Applicant has included herewith a complete claim set with insertions and deletions indicated by underlining and strikethrough (or double bracketing), respectively.

1.-53. (Canceled)

- 54. (Previously presented) An isolated nucleic acid molecule comprising a nucleic acid molecule selected from the group consisting of (a) SEQ ID NO:23, (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to the degeneracy of the genetic code, and (c) full-length complements of the nucleic acid molecules of (a) or (b).
- 55. (Canceled)
- 56. (Currently amended) An isolated nucleic acid molecule selected from the group consisting of
- (a) a fragment of a nucleic acid molecule consisting of a nucleotide sequence as set forth as SEQ ID NO:23, of at least [[50]]460 nucleotides, and
 - (b) full length complements of (a),

provided that the isolated nucleic acid molecule includes a sequence of contiguous nucleotides which is not identical to the nucleic acid sequence represented by SEQ ID NO:33.

57.-59. (Canceled)

- 60. (Previously presented) An isolated expression vector comprising an isolated nucleic acid molecule of claim 54 operably linked to a promoter.
- 61. (Canceled)

Reply to Office Action of January 8, 2008

62. (Previously presented) An isolated expression vector comprising a nucleic acid molecule of claim 54 and a nucleic acid encoding a MHC molecule.

- 63. (Canceled)
- 64. (Previously presented) An isolated host cell transformed or transfected with an expression vector of claim 60.
- 65. (Canceled)
- 66. (Previously presented) An isolated host cell transformed or transfected with an expression vector of claim 60 and further comprising a nucleic acid encoding a MHC molecule.
- 67-75. (Canceled)
- 76. (Currently amended) A kit for detecting the presence of the expression of a cancer associated antigen precursor comprising

a pair of isolated nucleic acid molecules,

one of which consists essentially of a molecule selected from the group consisting of (a) a 12–32 nucleotide contiguous segment of SEQ ID NO:23, and (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to the degeneracy of the genetic code,

the other of which consists essentially of a molecule selected from the group consisting of (a) a 12–32 nucleotide contiguous segment of the reverse complement of SEQ ID NO:23, and (b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to the degeneracy of the genetic code,

wherein the pair of isolated nucleic acid molecules <u>consists of SEQ ID NO:27 and SEQ ID NO:28 do not overlap each other.</u>

77-132. (Canceled)

Application No. 09/559,013 Reply to Office Action of January 8, 2008 4

Docket No.: L0461.70086US00

133. (Currently amended) The isolated nucleic acid molecule of claim 56, wherein the fragment has a size selected from the group consisting of at least: 75 nucleotides, 100 nucleotides and 200 nucleotides.

134.-137. (Canceled)